Clinical Conundrums in ITP, Dr. Mark Crowther (9/18/23) – Webinar Case

Speaker: Mark Crowther, MD MSc FRCPC FRSC
Chair, Department of Medicine
Leo Pharma Chair in Thromboembolism Research
McMaster University

Learning Objectives:

1. Identify common issues in the management of ITP.
2. Distinguish between those patients who do, and do not, require therapy.
3.  Appraise evidence for novel therapies in this area.

Answer and track your answers to these questions before watching the webinar:

Q1 : Which therapy is most likely to result in a safe platelet count 1 year after treatment discontinuation
a. Splenectomy
b. Steroids
c. Rituximab

Q2 : Secondary ITP is seen in association SLE
a. Commonly
b. Rarely
c. Almost never

Q3 : After a failed first course of steroids, most experts would
a. Provide a second course of steroids
b. Use rituximab
c. Use a tPO agonist

There will be a quiz following your video viewing.

Scientific Planning Committee

Dr. Pallavi Ganguli – Resident Physician, Hematology
Danyal Ladha – Resident Physician, Hematology
Dr. Joanne Britto – Clinical Fellow, Malignant Hematology (Lymphoproliferative Disorders)
Dr. Yan Xu – Fellow Physician, Hematology/Thrombosis
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician,
Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflict of Interest: None